Vigantoletten

Quick links to important sections

Vigantoletten

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vigantoletten

What is Vigantoletten? An Overview

Property Description
Active ingredient Colecalciferol (Vitamin D3)
Form Oral tablet, Oral liquid drops/solution
Pharmacological class Vitamin D Analog / Secosteroid
Common use Prevention and support of Vitamin D deficiency
Origin Derived (chemically synthesized)

What Kind of Medicine is Vigantoletten? (Identity, Classification, and Composition)

Vigantoletten is an oral pharmaceutical preparation containing the single active substance Colecalciferol (also known as Vitamin D3), classifying it as a vitamin D analog and a dietary supplement. This compound belongs to the pharmacological group of secosteroids and is structurally identical to the vitamin D the human body synthesizes endogenously in the skin upon sun exposure. Clinically recognized for its role in supporting mineral homeostasis, Colecalciferol is a single-ingredient product providing a precursor molecule—a prohormone—that requires metabolic activation within the body. Colecalciferol is generally preferred over Vitamin D2 for effectively raising and maintaining serum vitamin D concentrations in the body. The preparation is typically supplied as a solid oral tablet, though the substance is also found in liquid forms for easier administration to target groups such as infants.


What is the General Purpose of Vigantoletten? (Function and Benefit)

The core purpose of taking Vigantoletten is to maintain the body's capacity for proper mineral homeostasis by sustaining adequate levels of circulating vitamin D. Once the prohormone is metabolized into its active form, its primary function is to promote the efficient intestinal absorption of essential minerals, specifically calcium and phosphate. This mechanism is key to supporting skeletal health. Colecalciferol has an established role in the prophylaxis of vitamin D deficiency across various patient groups. This confirms that the medication is fundamental for maintaining the structural integrity and healthy mineralization of bone structure throughout life.

Regulatory References

  1. Cholecalciferol - StatPearls

What side effects are possible with Vigantoletten?

Possible Side Effects and Safety Information

The official safety profile of Colecalciferol is defined by its core action on mineral regulation, which structures the types of adverse reactions documented in regulatory sources.

Adverse effects are categorized by frequency, with hypercalcemia (high calcium levels in the blood) and hypercalciuria (excess calcium excretion in the urine) both classified as uncommon side effects. These effects are grouped under Metabolism and nutrition disorders and Renal and urinary disorders, reflecting the physiological mechanism of Vitamin D.

Less frequently, reactions are listed as rare, involving the Gastrointestinal disorders system, such as nausea, constipation, abdominal pain, flatulence, and diarrhea. Rare effects may also involve the Skin and subcutaneous tissue disorders, including rash, pruritus (itching), and urticaria (hives).

Serious adverse reactions are primarily associated with chronic or prolonged excessive intake, leading to toxicity known as Hypervitaminosis D. This serious condition can result in severe hypercalcemia and the risk of soft tissue calcification, including nephrocalcinosis (calcification of the renal tissue).

Safety constraints are explicit in regulatory documents. Colecalciferol is contraindicated in individuals with pre-existing conditions such as hypercalcemia, hypercalciuria, nephrolithiasis (kidney stones), or severe renal impairment. Special caution is advised for patients with sarcoidosis due to increased sensitivity, requiring monitoring of calcium levels, as described in official product information.

Overdose and Emergency Response

Overdose and when to seek help

The official overdose profile for Vigantoletten (Colecalciferol) is characterized by Hypervitaminosis D, which leads to Hypercalcemia (high calcium levels in the blood), a condition associated with severe and potentially life-threatening outcomes.

Documented Overdose Manifestations and Risks

Classification Officially Documented Statement
Symptom Cluster Overdose often presents with gastrointestinal symptoms, including nausea, vomiting, anorexia, and constipation, followed by systemic effects such as fatigue, muscle weakness, polyuria (frequent urination), and polydipsia (excessive thirst).
Severe Outcomes The risk profile includes the development of severe complications, such as nephrocalcinosis (calcification of kidney tissue) and irreversible renal failure. Chronic high-level exposure can also lead to widespread calcification of soft tissues and blood vessels, along with potential cardiac arrhythmias.
Population Note The regulatory profile notes that infants and patients with underlying chronic renal impairment are specifically at an increased risk of severe toxicity.

Emergency Actions Mandated by Regulators

If overdose symptoms or chronic toxicity are suspected, the official guidance strictly mandates two immediate actions: discontinuation of the product immediately and seeking immediate medical attention. The profile emphasizes that progressive Hypercalcemia may be severe enough to require emergency attention.

Treatment is officially defined as symptomatic and supportive, as no specific antidote is known. Hospital monitoring, including regular checks of serum calcium, urinary calcium, and kidney function (creatinine/urea), is required until levels normalize.

Therapeutic Uses of Vigantoletten

The primary role of Vigantoletten, which contains the active ingredient cholecalciferol (vitamin D3), is applied in addressing or managing symptoms related to systemic imbalance caused by vitamin D deficiency. Its therapeutic applications are relevant in contexts involving heightened systemic burden. The medicine is commonly used to help with managing disorders associated with insufficient vitamin D, such as rickets in children, osteomalacia (a softening of the bones) in adults, and osteoporosis.

The product is considered relevant for the prophylaxis (prevention) of vitamin D deficiency in individuals at recognizable risk and in conditions involving episodic or fluctuating manifestations like hypoparathyroidism. This approach contributes to easing the overall symptom load and helps address symptoms that create noticeable physiological strain.

The primary clinical contexts include the management of established vitamin D deficiency, prophylaxis of deficiency, and supportive treatment for osteoporosis.

“The support helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Support for Symptoms related to physical discomfort

Regulatory References

  1. EU/UK Public Assessment Report for Colecalciferol

Eligibility and Restrictions for Use

Who Can and Cannot Use Vigantoletten?

Eligibility for Vigantoletten (Colecalciferol) is determined strictly by regulatory guidelines, focusing on pre-existing metabolic and renal health. The medicine is contraindicated and must not be used by individuals with key metabolic imbalances, including hypercalcaemia (high blood calcium), hypercalciuria (high urine calcium), or hypervitaminosis D (vitamin D toxicity). Patients with severe renal impairment are also prohibited from use, as are those with nephrolithiasis (kidney stones).


Population Eligibility Rules

Population Group Regulatory Status
Most Adults, Infants, and Children Generally allowed for prophylaxis of deficiency, based on specific formulation strength.
Pediatric Use (Certain Strengths) Certain high-dose tablet formulations are not recommended or contraindicated for children under 12 or adolescents under 18.
Pregnancy and Lactation Not recommended for high-dose formulations; overdose must be avoided.
Sarcoidosis Use requires caution due to the increased risk of hypercalcaemia.
Non-Severe Renal Impairment Use requires caution and monitoring of calcium levels is necessary.

Use is generally permitted for high-risk populations, such as institutionalized individuals and those with malabsorption syndromes, provided they meet the basic eligibility criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Colecalciferol (Vitamin D3) is documented by regulatory authorities, focusing on metabolic effects, absorption interference, and pharmacodynamic consequences related to calcium balance. These interactions are classified based on the level of risk and resulting outcome.


Pharmacokinetic and Exposure-Altering Interactions

Interaction Type Interacting Substance/Class Official Documented Outcome
Reduced Effectiveness Anticonvulsants (e.g., Phenytoin, Phenobarbital), Rifampicin, Isoniazid The effect of Colecalciferol is reduced due to hepatic enzyme induction or inhibition of activation.
Reduced Absorption Ion-Exchange Resins (e.g., Cholestyramine), Mineral Oils, Orlistat These substances may reduce gastrointestinal absorption of the active ingredient, lowering its exposure.

Pharmacodynamic and Contraindicated Interactions

Interaction Type Interacting Substance/Class Official Documented Outcome
Contraindicated Vitamin D Analogues/Metabolites (e.g., Calcitriol) Co-administration is prohibited due to the severe and immediate risk of hypercalcaemia.
Hypercalcaemia Risk Thiazide Diuretics, Calcium Supplements Increases the risk of hypercalcaemia by reducing calcium excretion or increasing mineral load.
Increased Toxicity Cardiac Glycosides (e.g., Digitalis) Elevated calcium levels may potentiate the toxicity of these medicines.

Official labeling also notes population-specific cautions: caution is advised in patients with Sarcoidosis due to increased metabolism, and co-use with cardiac glycosides requires monitoring in elderly patients.

Mechanism of Action

Vigantoletten's mechanism is driven entirely by a complex endocrine process that converts the inactive precursor, Colecalciferol, into the biologically active hormone Calcitriol (1,25(OH)2D3). The full action requires two specific hydroxylation steps in the liver and kidneys, requiring the functional presence of specific enzymes in the liver and kidneys for activation.


The final active hormone, Calcitriol, functions as an agonist for the Vitamin D Receptor (VDR), a key nuclear transcription factor. This interaction forms a complex with the Retinoid X Receptor (RXR), which then binds to specific Vitamin D Response Elements (VDREs) on DNA. This engagement directly modulates gene transcription, controlling the cellular production of critical transport proteins like Calbindin, initiating the systemic effect.


The enhanced protein production translates into a multi-organ functional consequence, leading to the regulation of systemic mineral levels. The primary physiological effect is the dramatic increase in the active absorption of dietary calcium and phosphate from the small intestine. Concurrently, the mechanism promotes renal reabsorption of calcium, which results in the saturation levels necessary for bone matrix calcification processes and is required for proper neuromuscular conduction.

Dosage and Administration Information

The administration of Vigantoletten, which contains cholecalciferol, is strictly by the oral route, utilizing solid tablets, capsules, or liquid drop formulations. To promote proper absorption of the fat-soluble active substance, the dose is preferably taken with the main meal of the day.


Dosing and Frequency Patterns

Dosing regimens are categorized into an initial correction phase and a long-term maintenance phase. For the initial correction of an established deficiency, a daily dose ranging from 1,000 IU to 4,000 IU may be used, often for a period of about ten weeks. For cases of severe deficiency, high-dose regimens, such as 50,000 IU administered once a week for six to eight weeks, may be prescribed for rapid repletion.

Following the initial correction phase, patients typically transition to a long-term maintenance dose, generally 1,000 IU to 2,000 IU daily. This daily schedule is also the standard regimen used as an adjunct in osteoporosis treatment.


Administration and Handling Rules

Solid preparations must be swallowed whole with water. Liquid drops, commonly used for infants and young children, may be administered directly or mixed with food or liquids to ensure the full amount is consumed. The 1,000 IU tablet/capsule formulation is typically reserved for adolescents over 12 years of age and adults.

If a daily dose is missed, standard procedure involves skipping the forgotten dose if it is almost time for the next scheduled dose. A missed dose must not be doubled to compensate.

Recent Clinical Evidence

Vigantoletten: Recent Clinical Evidence

Overview of Vitamin D3 Research

Vigantoletten contains cholecalciferol (Vitamin D3), a substance essential for calcium homeostasis and bone health. Research has historically focused on its role in preventing and treating nutritional rickets and osteomalacia, conditions characterized by poor bone mineralization.

Core Areas of Study

Clinical evidence primarily addresses the effect of Vitamin D3 supplementation in populations with confirmed deficiency. Studies have examined whether increasing circulating levels of 25-hydroxyvitamin D is associated with improved intestinal calcium absorption and bone mineral density (BMD).

Findings from large-scale observational studies and randomized controlled trials (RCTs) generally support the use of Vitamin D3 for preventing deficiency and maintaining skeletal health in at-risk groups. Research has also explored its potential in other areas, although the evidence remains mixed or inconclusive in many of these areas, including immune function and cardiovascular health.

Key Research Focus

Population Studied Primary Focus of Research
Infants and Children Evaluating prevention of nutritional rickets.
Elderly Adults Examining the association between supplementation and bone mineral density, and whether it influences the risk of fractures.
Adults with Confirmed Low Levels Evaluating effectiveness in correcting serum 25-hydroxyvitamin D concentration.

It is important to note that Vitamin D3 is generally researched as part of a comprehensive strategy that includes adequate calcium intake, and research findings may be sensitive to baseline vitamin D status.

Frequently Asked Questions (FAQ)

Common questions about Vigantoletten (FAQ)


Q: Do you need a prescription from a doctor to buy Vigantoletten?

According to official regulatory classifications, the requirement for a prescription can depend on the strength of the tablet. Certain lower-dose formulations of Vigantoletten are designated as an over-the-counter (OTC) medicine in some countries, meaning they are available without a doctor's prescription. However, higher-dose preparations are generally reserved for treating confirmed deficiency and may require a prescription.


Q: Is Vigantoletten the same as just taking a regular Vitamin D supplement?

Vigantoletten is a brand name for a medicinal product containing Colecalciferol (Vitamin D3). As a pharmaceutical preparation, it is manufactured and monitored under the strict quality and content standards applied to regulated medicines. This is different from the standards applied to general 'dietary supplements' in many regions.


Q: What is the main difference between Vigantoletten and other forms of Vitamin D?

Vigantoletten contains the active substance Colecalciferol, which is chemically identical to Vitamin D3. Official medical literature often notes that Vitamin D3 is the form that is commonly utilized, as it is the same molecule the body naturally synthesizes. This form is often noted for efficiently raising and maintaining circulating vitamin D levels compared to other forms like Vitamin D2.


Q: Can women use Vigantoletten during pregnancy or while breastfeeding?

Official regulatory guidance indicates that low-dose Colecalciferol is commonly utilized or considered throughout both pregnancy and lactation for deficiency prevention. Higher doses are usually reserved for treating confirmed deficiency and, as stated in the product information, overdose must be avoided.


Q: What happens if a child accidentally takes an adult dose of Vigantoletten?

Accidental overdose carries a risk of developing Hypervitaminosis D, which leads to dangerously high calcium levels in the blood, known as hypercalcaemia. Signs of this serious reaction can include vomiting, fatigue, mental disturbances, and frequent urination. In cases where this occurs, regulatory information advises that medical attention be sought.


Q: What are the ingredients in Vigantoletten besides the active component?

The active substance is Colecalciferol. Official product information lists several inactive ingredients, or excipients, used in the tablets, which commonly include mannitol, maize starch, cellulose, silica, talc, and magnesium stearate. It is also documented that some formulations contain lactose or sucrose.


Q: If I am taking medication for high cholesterol, can I still take Vigantoletten?

Regulatory documents note that certain medications used to lower cholesterol, specifically a class known as ion-exchange resins (like Cholestyramine), may reduce the absorption of Colecalciferol in the digestive system. This interaction may decrease the effectiveness of Vigantoletten and concurrent use may require monitoring.


Q: Is there a maximum time frame for how long someone can take Vigantoletten?

Official documentation outlines an initial short-term correction phase for deficiency, typically lasting a few weeks. Following this, a patient often transitions to a maintenance dose, which is designed to be taken long-term to sustain healthy Vitamin D levels. Regulatory guidelines do not specify an absolute maximum duration for this maintenance use.


Q: Can Vigantoletten cause any weight gain or changes in appetite?

Official safety documentation does not list weight gain as a known adverse effect of this medicine. However, decreased appetite (anorexia) is listed as a symptom associated with the serious adverse reaction of high blood calcium levels (hypercalcaemia), a condition related to overdose.


Q: Why is this medicine available in different strengths, like 500 IU and 1000 IU?

The availability of different strengths is necessary to address varying therapeutic goals. Official dosing regimens differentiate between the amount needed for prophylaxis (prevention), the daily amount for long-term maintenance, and the higher amounts needed for the initial correction of a severe deficiency.


Q: How long does it usually take to see a difference after starting Vigantoletten?

Clinical information indicates that blood levels of Vitamin D generally take a few weeks of consistent daily supplementation to begin rising. The total time required to correct an established insufficiency or deficiency to an optimal level is typically measured in several months.


Q: Does Vigantoletten affect sleep patterns, like causing insomnia or making you tired?

Official safety profiles do not list changes to sleep patterns, such as insomnia, as a common or uncommon side effect. However, general fatigue is noted as a symptom associated with the serious adverse reaction of high blood calcium levels (hypercalcaemia), which occurs due to overdose.


Q: Can taking Vigantoletten cause any problems with your kidneys?

Official product information states that the medicine is contraindicated for people with severe renal impairment and a history of kidney stones (nephrolithiasis). Additionally, chronic overdose leading to high calcium levels can cause a serious complication called nephrocalcinosis, which is the calcification of kidney tissue.


Q: Does Vigantoletten contain any ingredients like gluten, lactose, or sugar?

Official documentation confirms that some tablet formulations of Colecalciferol contain excipients (inactive ingredients) such as lactose monohydrate and sucrose. Reviewing the full list of ingredients in the patient information leaflet is important, especially if there are known sensitivities to substances like milk sugar or other allergens.


Q: Does Vigantoletten interact with any herbal supplements?

Official regulatory guidance notes that there is often insufficient information available to confirm whether taking Colecalciferol alongside all types of complementary medicines or herbal remedies is safe. This lack of information suggests that a healthcare provider should be informed about all non-prescription items currently being used.


Q: Can Vigantoletten cause issues like feeling dizzy or having headaches?

Official safety listings for Colecalciferol sometimes include headache as a reported adverse effect. Dizziness and confusion are also noted as potential signs of serious reactions, such as the onset of high blood calcium levels (hypercalcaemia) or a severe allergic response.


Q: Is there any scientific debate about the required dosage of Vitamin D in general?

Official bodies in different countries and regions publish varying reference intakes and recommendations for daily Vitamin D requirements. This variation reflects ongoing scientific review and discussion regarding the optimal intake levels necessary to maintain general health and bone strength across diverse populations.


Q: Is Vigantoletten sometimes used by people who don't get much sun exposure?

Yes, official product indications state that the medicine is used for the prophylaxis (prevention) of Vitamin D deficiency. This includes individuals who are recognized as having limited effective sun exposure, such as those who consistently wear protective clothing or use high levels of sunscreens.


Q: What are the signs that Vigantoletten might be causing a negative reaction?

Regulatory safety documents describe uncommon side effects that may affect the stomach and gut (e.g., nausea, diarrhea) or the skin (e.g., rash, itching). Signs of a potentially serious reaction are those linked to high calcium levels (hypercalcaemia), such as frequent urination, vomiting, severe thirst, or confusion.


Q: Is Vigantoletten intended for daily or less frequent use?

Official product information details various dosing regimens. The medicine can be prescribed for daily use as a long-term maintenance dose. However, higher-dose formulations are also available, which are intended for less frequent administration, such as weekly or monthly dosing, for the initial correction of deficiency.


Q: What is the difference in how Vigantoletten and Vitamin D drops are absorbed?

Both the tablet and liquid drop formulations contain the same active substance, Colecalciferol, which is fat-soluble. Official guidelines state that both forms should be administered with the main meal of the day to promote optimal absorption into the body. No fundamental difference in the actual metabolic absorption mechanism is documented between the two oral preparations.


Q: Can Vigantoletten be taken at the same time as iron supplements?

Regulatory documentation on drug interactions does not specifically list iron supplements among the medicines that interfere with the absorption or effects of Colecalciferol. However, a healthcare provider should be informed about the full profile of medications and supplements being used.

How should Vigantoletten be stored and disposed of?

How to Store and Dispose of Vigantoletten (Colecalciferol)

The storage and disposal of Vigantoletten must strictly adhere to the conditions documented in official regulatory labeling to ensure product integrity.

Official Storage Requirements

Storage Condition Requirement
Temperature Store at a temperature below 25 C.
Protection Must be protected from light and protected from moisture.
Container Keep the medicine stored in the original package.

Like all medicines, Vigantoletten must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired Vigantoletten must be disposed of in accordance with local requirements, typically by returning it to a pharmacy or designated collection point. The medicine must not be discarded via wastewater or regular household waste, as mandated by environmental protection protocols in regulatory labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vigantoletten found in:

A-Z Index: